DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA)
CAPS Rating:
A dermatology company, which is engaged in the development and marketing Levulan photodynamic therapy and other products for common skin conditions.
A dermatology company, which is engaged in the development and marketing Levulan photodynamic therapy and other products for common skin conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Company earnings turned positive 2nd hald of 2011 and look to be continuing down that path. Last year grew +20% revenues. Thompson puts street est of .13/.12 for 4th qtr. Y/y would equal .30/.11 p/s.